| gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma DJ Schwartzentruber, DH Lawson, JM Richards, RM Conry, DM Miller, ... New England Journal of Medicine 364 (22), 2119-2127, 2011 | 1086 | 2011 |
| Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma NN Senzer, HL Kaufman, T Amatruda, M Nemunaitis, T Reid, G Daniels, ... Journal of Clinical Oncology 27 (34), 5763, 2009 | 709 | 2009 |
| Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein AP Ferretti, T Kula, Y Wang, DMV Nguyen, A Weinheimer, GS Dunlap, ... Immunity 53 (5), 1095-1107. e3, 2020 | 317 | 2020 |
| Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C … A Testori, J Richards, E Whitman, GB Mann, J Lutzky, L Camacho, ... Journal of Clinical Oncology 26 (6), 955-962, 2008 | 282 | 2008 |
| Comparative analysis of laparoscopic versus open splenectomy LM Brunt, JC Langer, MA Quasebarth, ED Whitman The American journal of surgery 172 (5), 596-601, 1996 | 255 | 1996 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 226 | 2018 |
| Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma AA Sarnaik, O Hamid, NI Khushalani, KD Lewis, T Medina, HM Kluger, ... Journal of Clinical Oncology 39 (24), 2656-2666, 2021 | 197 | 2021 |
| Nerve protecting dissection device ED Whitman US Patent 10,022,090, 2018 | 189 | 2018 |
| Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic … SS Agarwala, J Glaspy, SJ O’Day, M Mitchell, J Gutheil, E Whitman, ... Journal of clinical oncology 20 (1), 125-133, 2002 | 189 | 2002 |
| A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma KD Lewis, W Samlowski, J Ward, J Catlett, L Cranmer, J Kirkwood, ... Investigational new drugs 29, 161-166, 2011 | 166 | 2011 |
| Complications associated with the use of central venous access devices ED Whitman Current problems in surgery 33 (4), 309-378, 1996 | 150 | 1996 |
| Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases MS Hughes, J Zager, M Faries, HR Alexander, RE Royal, B Wood, J Choi, ... Annals of surgical oncology 23, 1309-1319, 2016 | 143 | 2016 |
| A persistent outbreak of measles despite appropriate prevention and control measures RM Davis, ED WHITMAN, WA Orenstein, SR Preblud, LE Markowitz, ... American journal of epidemiology 126 (3), 438-449, 1987 | 124 | 1987 |
| Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma MS Mitchell, J Abrams, JA Thompson, M Kashani-Sabet, RC DeConti, ... Journal of Clinical Oncology 25 (15), 2078-2085, 2007 | 104 | 2007 |
| Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study HL Kaufman, T Amatruda, T Reid, R Gonzalez, J Glaspy, E Whitman, ... Journal for immunotherapy of cancer 4, 1-8, 2016 | 103 | 2016 |
| A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma AY Bedikian, J Richards, D Kharkevitch, MB Atkins, E Whitman, ... Melanoma research 20 (3), 218-226, 2010 | 103 | 2010 |
| Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database RL White, GD Ayers, VH Stell, S Ding, JE Gershenwald, JC Salo, ... Annals of surgical oncology 18, 3593-3600, 2011 | 98 | 2011 |
| An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 RJ Sullivan, MB Atkins, JM Kirkwood, SS Agarwala, JI Clark, MS Ernstoff, ... Journal for immunotherapy of cancer 6, 1-23, 2018 | 83 | 2018 |
| Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. RHI Andtbacka, BD Curti, H Kaufman, GA Daniels, JJ Nemunaitis, ... Journal of Clinical Oncology 33 (15_suppl), 9030-9030, 2015 | 75 | 2015 |
| Venographic surveillance of tunneled venous access devices in adult oncology patients MDK Horne, DJ May, HR Alexander, EP Steinhaus, ED Whitman, ... Annals of Surgical Oncology 2, 174-178, 1995 | 64 | 1995 |
